Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

InMed Pharmaceuticals (INM) Accumulated Depreciation & Amortization (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Accumulated Depreciation & Amortization data on record, last reported at $1.3 million in Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization fell 1.25% year-over-year to $1.3 million; the TTM value through Jun 2025 reached $1.3 million, down 1.25%, while the annual FY2025 figure was $1.3 million, 1.25% down from the prior year.
  • Accumulated Depreciation & Amortization reached $1.3 million in Q2 2025 per INM's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $1.4 million in Q2 2024 and bottomed at $244261.0 in Q3 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $885188.6, with a median of $976752.5 recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 123.64% in 2022, then fell 1.86% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $320520.0 in 2021, then soared by 123.64% to $716800.0 in 2022, then surged by 56.84% to $1.1 million in 2023, then grew by 1.43% to $1.1 million in 2024, then increased by 17.38% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $1.3 million in Q2 2025, $1.2 million in Q1 2025, and $1.1 million in Q4 2024.